Merck KGaA has posted a strong set of figures for the third quarter this morning, which reveal that earnings jumped and revenues reached record levels.
The Darmstadt, Germany-based group’s net income came in at 210.8 million euros, up 46%, while revenues increased 25.0% to 2.44 billion euros. The figures were boosted by the contribution of the US laboratory equipment specialist Millipore which was acquired in July for 5.10 billion euros.
Turnover at the Merck Serono unit rose 5.7% to 1.39 billion euros, driven by sales of the multiple sclerosis drug Rebif (interferon beta-1a) which climbed 6.8% to 407 million euros. The colorectal/head and neck cancer drug Erbitux (cetuximab) increased 17% to 207 million euros, while its Glucophage (metformin) diabetes products rose 3.3% to 79 million euros, although the beta blocker Concor (bisoprolol) franchise was down 19% to 84 million euros.
Merck’s thyroid treatments, notably Euthyrox (levothyroxine), were flat at 41 million euros, while sales of the fertility drug Gonal-f (follitropin) increased 3.9% to 115 million euros. The growth hormone Saizen (somatropin) rose 17% to 56 million euros.
Sales at Merck's consumer health division inched up 1.7% to 125 million euros, while liquid crystals revenues jumped 21% to 255 million euros. For the full year, the group has reduced its revenue growth rate forecast to 19% from 21%, while operating result is now expected to rise 70%, down from a previous estimate of 90%.